Recombinant human G-CSF has been used to treat severe congenital neutropenia (Skokowa et al., 2017), chemotherapy-induced neutropenia (Mehta et al., 2015), and in HSCT recipients as well. Here, CSF3 is linked to severe congenital neutropenia.